NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, announced today preclinical data demonstrating potent activity against multi-drug resistant Gram-negative and Gram-positive bacteria with multiple compounds from three novel classes of antibacterial agents developed in the Company’s RX-04 program. Rib-X also presented data confirming the novel classes directly impact ribosome function and exert their antibacterial activity by interfering with protein synthesis. The data were presented in a podium talk and three poster sessions on May 7 and 8, 2011 at the 21st Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID)/27th Annual International Congress of Chemotherapy (ICC) in Milan, Italy.
